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Background: Polymorphisms within the apolipoprotein-E (APOE), Methylenetetrahydrofolate reductase (MTHFR) and
Angiotensin I-converting enzyme (ACE) genes has been associated with cardiovascular and cerebrovascular disorders,
Alzheimer’s disease and other complex diseases in various populations. The aim of the study was to analyze the allelic
and genotypic frequencies of APOE, MTHFR C677T and ACE I/D gene polymorphisms in the Zambian population.
Results: The allele frequencies of APOE polymorphism in the Zambian populations were 13.8%, 59.5% and 26.7% for
the ε2, ε3 and ε4 alleles respectively. MTHFR C677T and ACE I/D allele frequencies were 8.6% and 13.8% for the T and D
minor alleles respectively. The ε2ε2 genotype and TT genotype were absent in the Zambian population. The genetic
distances between Zambian and other African and non-African major populations revealed an independent variability
of these polymorphisms.
Conclusion: We found that the APOE ε3 allele and the I allele of the ACE were significantly high in our study
population while there were low frequencies observed for the MTHFR 677 T and ACE D alleles. Our analysis of the
APOE, MTHFR and ACE polymorphisms may provide valuable insight into the understanding of the disease risk in the
Zambian population.
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The burden of non-communicable diseases such as stroke
and cardiovascular disease is increasing in Sub-Saharan
Africa (SSA) [1,2]. Their development is most likely
caused by the interaction of multiple genetic factors and
known risk factors (hypertension, diabetes, dyslipidemia,
and smoking). One of the challenges for translating dis-
ease associated polymorphisms into clinical application is
the lack of knowledge regarding the frequency of the poly-
morphism in the targeted population. Without this infor-
mation, population-attributable risk remains unknown. In
addition, factors that could affect the association of the al-
lele with disease, either positively or negatively, such as
ethnicity and gender, may not be possible to determine
without population based allele frequencies [3].
A number of genetic polymorphisms, such as Apolipo-
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distribution, and reproduction in any medium(MTHFR) and Angiotensin I-converting enzyme (ACE),
have been studied in relation to age-related disorders.
Specific polymorphisms in these genes have been impli-
cated in various complex disorders including cerebrovas-
cular disease (CVD), coronary artery disease (CAD) and
Alzheimer’s disease (AD) [4-7].
For example, ACE is an enzyme of the renin-angiotensin
system (RAS) catalyzing the conversion of angiotensin I to
angiotensin II which is implicated in fluid and electrolytes
balance. Angiotensin II has vasoconstrictor effect hence
contributing to systemic blood pressure control, it also in-
hibits the release of acetylcholine (anticholinergic effect)
and has pro-inflammatory effect [8].
The ACE polymorphism is characterized by the pres-
ence (insertion or I) or the absence (deletion or D) of
Alu Ya5 inside intron 16 giving three possible genotypes
(homozygote II, heterozygote ID and homozygote DD).
The frequency of the insertion/deletion I/D polymorph-
ism of the ACE gene has been widely investigated since
it was identified by Rigat et al. [8]. The authors further
observed that the highest serum ACE activity was in thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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lowest activity was found [9]. Many authors have sug-
gested the ACE I/D variants predisposes the individual to
CAD, hypertension, stroke and diabetes mellitus [10-17].
Several studies have reported a reduction of the incidence
and rate of the cognitive decline in AD after starting treat-
ment with RAS-acting antihypertensive drugs (ACE inhib-
itors) and angiotensin receptor blockers (ARB) [18].
The APOE gene encodes a protein which is essential for
the normal catabolism of triglyceride rich lipoprotein con-
stituents and modulates lipoprotein metabolism. The APOE
gene is polymorphic with three common alleles, ε2, ε3 and
ε4 resulting in three distinct protein isoforms Ε2, Ε3 and Ε4
determined by the two amino acid substitutions (R112C and
C158R). Several investigations have suggested that the
APOΕ4 is the ancestral allele [19,20] even though it is the
risk allele in many diseases such CAD [4], CVD [21] and
AD [22]. MTHFR is a folate related enzyme important for
remethylation of homocysteine to methionine. Elevated total
plasma homocysteine (t-Hcy) concentration was found to
be correlated with MTHFR C677T polymorphism. A com-
mon polymorphism of the MTHFR gene, C677T, has been
reported to be associated with reduced enzyme activity and
increased t-Hcy levels [23] and hence, an independent risk
factor for stroke, CAD, and AD [24]. The allelic frequencies
of these specific polymorphisms in the APOE, MTHFR and
ACE genes substantially varies in different regions of the
world and among ethnic groups [3,19,25,26] and have not
yet been studied in the Zambian population, hence, associ-
ation of them with stroke, CAD, AD, and other common
non-communicable diseases in this population is unclear.
Zambia, officially the Republic of Zambia, is a landlocked
country in the central part of southern Africa. Zambia
covers an area of 752,614 square kilometers (290,586 square
miles) and has a population of almost 13 million, giving
the country one of the lowest populations-to-land ratios in
Africa. It borders the Democratic Republic of the Congo to
the north, Tanzania on the northeast, Malawi on the east,
Mozambique, Zimbabwe, Botswana, and Namibia to the
south, and Angola on the west [27]. The original inhabitants
of all of modern day Zambia, except Western Province, are
called Batwa (Khoisan). They were hunters and gatherers
who lived a nomadic life. The Khoisans were the only inhab-
itants of most of Zambia until the 4th century, when they
were displaced by the Bantu who started to migrate from
the north.Between the 15th century (or possibly earlier) and
the 18th century, various groups of Bantu migrants from the
southern Congo settled in Zambia [28]. Zambia was influ-
enced by two “invasions” in the mid-19th century. Shaka’s
Zulu empire in South Africa set in motion a series of migra-
tions, commonly referred to as the mfecane; groups of peo-
ples, including the Ngoni. The other invasion came in the
form of traders from the north. The territory of the present
Zambia, being far inland, did not have direct contact withnon-Africans until relatively recently in its history. The
traders from the north (Nyamwezi, Arabs, and Swahili) drew
Zambia into long-distance trading systems [28]. At present
Zambia has a mixture of 72 ethnic tribes. However, there
are seven (Chewa, Bemba, Lunda, Lozi, Kaonde, Luvale, and
Tonga) major ethnic groups who belong to the Bantu
people. The Tonga people were one of the first cultures to
settle in Zambia. Industrialization and urbanization has seen
these ethnically different people brought together by eco-
nomic interests.
In this study we have evaluated the prevalence of APOE,
MTHFR, and ACE gene polymorphisms in the Zambian
population and compared those frequencies with African
and other populations to provide baseline epidemiological
data for future clinical investigations of CVD, CAD, AD,
and other diseases in Zambia.
Methods
Sample collection
Blood samples were obtained from one hundred and sixteen
(68 women, 48 men) unrelated subjects. The study included
subjects between 25 and 60 years (mean age 44 ± 16 years),
who indicated their ancestry and belonged to one of 72 eth-
nic Zambian tribes. All individuals were recruited as part of
Zambian Stroke Study [29,30]. Available clinical records
were analyzed for exclusion of major neurological diseases.
Subjects known to have risk factors for stroke (hypertension,
severe coronary artery disease, diabetes mellitus and hyper-
lipidemia) were excluded from the study. Pregnant women
and HIV positive subjects were also excluded from the
study. All participants gave written informed consent and
the study was approved by the Biomedical Research Ethics
Committee of the University of Zambia.
Genetic analysis
Whole blood was collected in 4 ml EDTA tubes and
stored at 4 degrees Celsius prior to DNA extraction. The
DNA extraction was performed using silica-gel-based
membrane with vacuum technology (QIAamp DNA Mini
Kit (250) (QIAgen, London, UK).
Genotyping was performed using fluorescent-labeled
PCR technology with ABI TaqMan probes and chemistry
(Applied Biosystems, Foster City, CA), amplification was
performed with an ABI7900 Real-Time PCR system and
analysis performed using SDS 2.2.2 software. Positive and
negative controls where included on all TaqMan assay
plates. Positive or ambiguous results in the TaqMan assay
were also confirmed / resolved with direct sequencing.
Statistical analysis
We determined genetic distance using Carvalli-Sforza
and Edwards (1967) method [31] in order to give an
overview of the relationship between the Zambian and
other populations. The chi-square test was used to test
Table 1 Allele and genotype frequencies of the APOE, MTHFR and ACE polymorphisms and HWE in the Zambian
population (n = 116)
Polymorphism Allele Frequency Genotype % observed % expected HWE
APOE p = 0.456
Ε2 0.14 Ε2Ε2 0 1.9 X2 = 4.684
Ε3 0.6 Ε3Ε3 32.8 35.4




MTHFR C677T p = 0.540
C 0.91 CC 82.8 83.5 X2 = 1.233
T 0.09 CT 17.2 15.7
TT 0 0.74
ACE D/I p = 0.005
D 0.14 DD 5 1.9 X2 = 10.472
I 0.86 ID 17.2 23.8
II 77.6 74.3
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expected in the Hardy-Weinberg equilibrium (HWE).
Differences with other populations were assessed using
chi-square contingency test.
Results
Genotype and allele frequencies for the Zambian popu-
lation were as shown in Table 1. Genotyping call-rate
was greater than 98% with less than 2% of samples re-
quiring sequencing to resolve or confirm the genotype
data. The distribution of MTHFR and APOE genotypesTable 2 Gender frequencies of the APOE, MTHFR and ACE pol
Polymorphism Allelic frequencies
m = 102 f = 130








I 0.873 0.854conformed to Hardy-Weinberg equilibrium (HWE) with
p = 0.540 and p = 0.456 respectively, while the ACE allele
distribution was not according to HWE (p = 0.005) due to
an increase in rare minor allele homozygotes. There was
no statistically significant difference between male and fe-
male data for APOE, MTHFR and ACE polymorphisms
(Table 2). Our analysis of the APOE gene showed that the
rare E2E2 genotype was absent in our sample. In addition,
there was no significant difference between the frequency of
the ε3ε3 and ε3ε4 genotypes (p > 0.999) which were the most
frequent genotypes observed. The Ε3 allele of APOEymorphisms in the Zambian population
Genotypic frequencies
p m= 51 f = 65 p
0.57 Ε2Ε2 0 0
0.52 Ε3Ε3 0.314 0.34 0.47
0.53 Ε4Ε4 0.078 0.08 0.62
Ε2Ε3 0.235 0.2 0.41
Ε2Ε4 0.039 0.08 0.33
Ε3Ε4 0.333 0.31 0.46
0.37 CC 0.804 0.85 0.36
0.37 CT 0.196 0.15 0.36
TT 0 0
0.42 DD 0.039 0.06 0.46
0.42 ID 0.176 0.17 0.55
II 0.784 0.77 0.51
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while Ε2 allele had a frequency of 0.138, and Ε4 0.267.
The distribution of the APOE allele frequencies in the
Zambian population has an intermediate position among
other African populations. As shown in Table 3 and Figure 1,
pooled APOE allele frequencies of the Zambian population
was close to Tswanas [32], Ugandans [33], Ghanaians [32],
and Tanzanians [34].
The C allele of the MTHFR C677T polymorphism was
higher than T allele (p < 0.0001) with frequency of 0.914Table 3 The APOE allele frequencies in the African population
n ε
North Africa
Mauritanians [35] 20 0
Moroccans [36] 100 0
Tunisians [37] 180 0
West Africa
Ghanaians [32] 110 0
Gabonese [35] 25 0
Nigerians [38] 365 0
Bombareans (Mali) [35] 16 0
Guineans [35] 30 0
Beninese [19] 97 0
Togolese [35] 19 0
Djernas (Niger) [35] 16 0
Haoussas (Niger) [35] 37 0
Burkinabese [35] 20 0
Songhais (Mali) [35] 17 0
Senegalese [35] 33 0
East Africa
Ethiopians [19] 164 0
Ugandans [33] 140 0
Tanzanians [34] 143 0
Rwandese [35] 21 0
Kenyans [34] 61 0
Southern Africa
Zambians (current study) 116 0
Tswanas [32] 100 0
South Africans [2] 505 0
Sudanese [35] 103 0
Khoisans [39] 247 0
Malagasy [35] 22 0
Central Africa
Central Africa Republicans (Pygmies) [35] 70 0
Congolese (Congo DR) [35] 24 0
Other
Sub-Saharans(SSA) [35] 470 0and 0.086 respectively. The TT genotype was absent in
the Zambian population.
Multidimensional Scaling (MDS) analysis of the MTHFR
C677T polymorphism in the African populations, includ-
ing the Zambian population (Figure 1, Table 4) showed
a close relationship with previous studies on the Bantu
populations [40].
The current study found that, based on MTHFR C677T
polymorphism, Zambian population was closer to coastal
Togo and Moroccans were found to be furthest froms
2 ε3 ε4 p
.08 0.83 0.1 0
.07 0.85 0.09 0
.04 0.87 0.09 0
.15 0.61 0.24 0.89
.12 0.68 0.2 0.48
.03 0.68 0.3 0.03
.06 0.72 0.22 0.12
.23 0.6 0.17 0.1
.1 0.74 0.16 0.11
.32 0.47 0.21 0.01
.06 0.81 0.13 0.01
.03 0.78 0.19 0.01
.38 0.5 0.13 0
.21 0.74 0.06 0
.03 0.94 0.03 <0.0001
.03 0.81 0.14 0
.16 0.59 0.25 0.85
.14 0.65 0.21 0.66
.1 0.67 0.24 0.62
.09 0.59 0.32 0.5
.14 0.6 0.27 current study
.15 0.57 0.29 0.86
.190 0.52 0.29 0.43
.08 0.62 0.29 0.49
.08 0.55 0.37 0.2
.23 0.59 0.18 0.12
.06 0.54 0.41 0.05
.04 0.63 0.33 0.06
.12 0.71 0.18 0.27
Figure 1 Genetic relationships between populations represented by Multidimensional Scaling Analysis for APOE and MTHFR.
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data which shows that the frequency of homozygous mu-
tated genotype TT was absent in most of the investigated
African populations [45] According to Murry et al. [46],
this data suggests the lethal nature of this genotype in
most SSA populations.
The genotypic data for ACE shows that the II genotype
was higher than the ID genotype (p < 0.0001) and the
DD genotype (p < 0.0001) in the Zambian population.
The ACE polymorphism displayed I and D allele fre-
quencies at 0.862 and 0.138 respectively.The data shows that APO ε3, MTHFR 677C and ACE I
alleles were most widespread in the Zambian population.
Extensive interethnic variations in the frequency of I and
D alleles have been reported worldwide for various pop-
ulations (Table 5).Discussion
In this study we have analyzed for the first time poly-
morphisms of the APOE, MTHFR and ACE genes in the
Zambian population. This constitutes an approach to
Table 4 The MTHFR C677T polymorphism allele
frequencies in the African populations
n C T p
North Africa
Moroccans [36] 182 0.73 0.27 <0.0001
West Africa
Gambians [40] 24 0.94 0.06 0.69
Nigerians [41] 25 0.94 0.06 1
Burkinabes [42] 382 0.95 0.06 0.18
Coastal Togolese [43] 127 0.92 0.08 1
Inland Togolese [43] 68 0.94 0.06 0.58
Coastal Beninese [43] 270 0.9 0.1 0.85
Ghanaians [44] 174 0.92 0.08 1
East Africa
Kenyans [40] 61 0.95 0.05 0.55
South Africa
Zambians 116 0.91 0.09 Current study
Malagasy [40] 97 0.93 0.07 0.61
Central Africa
Pygmies [40] 8 0.94 0.06 1
Other
Bantu [40] 44 0.91 0.09 1
SSA [40] 234 0.93 0.07 0.51
Table 5 Allele frequencies of the ACE gene in different
ethnic groups
ACE allele frequency
n I D P
North Africa
Moroccans [36] 182 0.23 0.77 <0.0001
Egyptians [47] 188 0.28 0.72 <0.0001
Algerians [15] 48 0.27 0.73 <0.0001
Tunisians [15] 47 0.24 0.76 <0.0001
West African
Nigerians [48] 80 0.41 0.59 <0.0001
East Africa
Sudanese [49] 121 0.36 0.64 <0.0001
Somalis [49] 53 0.27 0.73 <0.0001
South Africa
Zambians 116 0.86 0.14 Current study
Other
Omanis [49] 124 0.29 0.71 <0.0001
African Americans [15] 40 0.3 0.7 <0.0001
Emiratis [50] 159 0.34 0.66 <0.0001
Greeks [51] 84 0.42 0.58 <0.0001
Brazilians [52] 65 0.42 0.58 <0.0001
Chinese, Dahur [53] 84 0.43 0.57 <0.0001
Caucasians [54] 733 0.54 0.46 <0.0001
Indians [55] 166 0.54 0.46 <0.0001
Japanese [56] 136 0.65 0.35 <0.0001
Chinese [57] 189 0.71 0.29 0
Pima Indians [58] 305 0.71 0.29 0
Mexican Teeneks [59] 64 0.78 0.22 0.21
Yanomami Indians [48] 49 0.85 0.15 1
Samoans [48] 58 0.91 0.09 0.46
Australian Aborigines [60] 184 0.97 0.03 0
Abazians [46] 126 0 1 <0.0001
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CAD, and AD in this population.
In our study population the APOE allele frequencies
of ε2 (0.138), ε3 (0.595), and ε4 (0.267) were within the
reported range of African populations [19] and the ε3
was the most prevalent. These allele frequencies varied
significantly between Zambian and the North African
populations such as Moroccans [36] and Tunisians [37].
The variation may be explained by extensive intermixing
of the North African populations with Arab, Jewish and
other Western Eurasian populations.
The APOE ε2 allele frequency range between the
Zambian and other African populations was from 7%
(Tswana, Botswana) to 11.1% in Haoussa’s of Niger. This
variation may be explained according to the ethnolinguis-
tic classification of the African population which identifies
the Haoussas as belonging to the Afro-asiatic macro-
family while the Zambian population can be classified
within the Niger-Kordofanian, the largest of the four
ethnolinguistic African macro-families [61]. The APOE ε3
allele frequency range between the Zambian population
and other African populations was from 4% (Malagasy
[35]) to 34.4% (in Senegalese [35]). The variation of APOE
ε4 allele frequency between the Zambian and other
African populations was as low as 1.8% between Zambianand Tswana [32] populations and as high as 23.7% be-
tween the Zambian and Senegalese populations.
Patterns of genetic variation in modern African popula-
tions are shaped by demographic forces such as the Bantu
migration [62]. Bantu speakers from West Africa prac-
ticing agricultural subsistence farming migrated through-
out SSA and subsequently admixed with indigenous
populations [61]. According to Gerdes et al. [63], popula-
tions with long-established agricultural economy such as
the West African, [43,64] have higher ε3 allele frequency
compared to other populations. Higher frequencies of
APOE ε3 allele were found in populations around the
Middle East probably because they have a longer estab-
lished agricultural economy compared to West Africa,
with the exception of Senegal [19].
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erogeneous among African [2,47,63] and other popula-
tions [26] (Figures 1,2). This heterogeneity illustrates the
geographical and ethnic variations resulting from the
evolutionary process. It has been suggested that APOE
ε2 and ε3 alleles arose by mutation of the ε4 allele [19].
Past studies have showed that the ε3 allele is more
widely distributed probably because of positive selection
for this allele in these regions [19,26].
It was found that the APOE ε4 (ancestral) allele frequency
is higher in the Khoisan population than the rest of the
Bantu populations [2,26]. According to this data it was sug-
gested that there is a flow of the ε4 allele from the Khoisan
to other Bantu populations [19]. However, it is not clear if
the increasing of CAD, CVD and AD in the African popula-
tions is associated with the ε4 allele frequency. Since the
African populations are characterized by greater levels of
genetic diversity [63], the association of CAD, CVD, and AD
with the ε4 allele frequency needs to be investigated in each
of the major ethnic groups of the Zambian population.
Our study showed that C allele of the MTHFR C677T
polymorphism was higher than T allele (p < 0.0001) with
the TT genotype completely absent. The frequency of
MTHFR C677T polymorphism has not been widely stud-
ied in African countries. However, few published studiesFigure 2 Distribution of the APOE ε4, MTHFR 677 T and ACE D alleleshowed that the 677TT genotype and the 677 T allele are
markedly lower (below 10%) in the African populations
than other ethnic groups [40-46,65-68].
For instance whites in Europe had 677TT frequency
range of 8% to 18% [40] while this frequency for whites
outside Europe ranged from 10 to 14% [67]. Amerindians
from Brazil had 677TT frequency range of 21% [40].
The difference in the MTHFR alleles among African and
other ethnic groups is not yet known. Studies in last decade
have shown positive correlation between concentration of
folate and the frequency of the 677 T allele [43,45], and hy-
pothesized of gene-nutrient interaction between MTHFR
and folate status [43]. On the basis of these data it was sug-
gested that adequate folic intake in a given population may
increase the frequency of the 677 T allele as described in
Europeans [45] and Americas [66]. Low frequency of the
677 T allele in African populations, including Zambian po-
pulation, is probably influenced by folate deficiency due to
malnutrition and infectious impairing intestinal absorption
of folate [46,67].
It has been reported that in P. falciparum malaria, there
is a correlation between plasma homocysteine (Hcy) con-
centrations and malaria severity [42,68]. Some authors
suggested that the 677 T carriers with increased level of
Hcy are more vulnerable to malaria in SSA [42]. Chronicfrequencies in the African populations.
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risk factor for severe anemia, especially in children. Selec-
tion for the 677 T allele has been reported in relation to
folate intake [69].
Unlike the APOE polymorphism, ACE I/D polymorph-
ism has not been widely studied among the African popu-
lations. In this study, the frequency of the D allele in the
Zambian population was significantly lower (p < 0.0001)
than other African countries. This may be explained by im-
portant gene flow between the North African and other
Eurasian populations, as it was suggested regarding APOE
allele frequencies.
In our data, the ACE polymorphism frequency of the
I allele was significantly prevalent compared to D allele
(p < 0.0001). However, other studies have reported a high
frequency of the D allele in the African populations
[17]. The II genotype was higher than the ID genotype
(p < 0.0001) and the DD genotype (p < 0.0001) in the
Zambian population. The discrepancies in allele and geno-
type frequencies between Zambian and other populations
need further investigations.
The frequency of the D allele of the ACE I/D poly-
morphism ranged from 0.03 among Australian aborigines
to 1.00 among the Abazians in Europe [70-73]. It was re-
ported that the DD was less frequent in Asians than non-
Asians [73,74].
Previous investigations have suggested a genetic pre-
disposition of ACE I/D polymorphism with CAD [75,76],
CVD [77], diabetes mellitus [78] However, there were
significant inter-ethnic variations [17,70,71]. There was
no statistically significant gender difference in our study
group for the investigated polymorphisms.
In interpreting the findings of this study it is essential to
consider its limitations. The small sample size cannot be
representative of all the Zambian population. However,
this will be a stepping stone to larger ongoing clinical and
genetic studies of stroke in the Zambian population. It is
apparent that gender, age, ethnic tribe are important fac-
tors in the study for analysis of the candidate gene poly-
morphism for diseases. Other limitations of this study
include lack of coverage from most African countries, par-
ticularly regarding the studies of the MTHFR C677T and
the ACE I/D polymorphisms.
Conclusion
We found that the APOE ε3 allele and the I allele of the
ACE were significantly high in our study population while
there were low frequencies observed for the MTHFR
677 T and ACE D alleles. Our analysis of the APOE,
MTHFR and ACE polymorphisms may provide valuable
insight into the understanding of the disease risk in the
Zambian population. However, our findings need to be
compared with the clinical implication through additional
studies within the Zambian population. The present studywill serve as a template for future investigations of the
prevalence of these genetic markers in larger population
samples and their possible association with CAD, CVD
and AD in the Zambian population.
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